Why is Shanghai Serum Bio-Technology Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 16.43%
- The company has been able to generate a Return on Capital Employed (avg) of 16.43% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 1.64% and Operating profit at 5.83% over the last 5 years
3
Flat results in Sep 25
- DEBT-EQUITY RATIO (HY) Highest at -69.53 %
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.83 times
4
With ROE of 3.97%, it has a fair valuation with a 0.92 Price to Book Value
- Over the past year, while the stock has generated a return of 34.79%, its profits have risen by 0.8%
5
Market Beating Performance
- The stock has generated a return of 34.79% in the last 1 year, much higher than market (China Shanghai Composite) returns of 22.49%
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shanghai Serum Bio-Technology Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanghai Serum Bio-Technology Co., Ltd.
143.02%
2.59
38.15%
China Shanghai Composite
21.28%
1.58
14.20%
Quality key factors
Factor
Value
Sales Growth (5y)
4.49%
EBIT Growth (5y)
2.30%
EBIT to Interest (avg)
40.36
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.18
Tax Ratio
10.03%
Dividend Payout Ratio
79.41%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.43%
ROE (avg)
4.24%
Valuation Key Factors 
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
1.51
EV to EBIT
18.57
EV to EBITDA
14.16
EV to Capital Employed
2.61
EV to Sales
4.61
PEG Ratio
25.43
Dividend Yield
NA
ROCE (Latest)
14.06%
ROE (Latest)
4.25%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Movement
4What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 80.2 MM
RAW MATERIAL COST(Y)
Fallen by -8.12% (YoY
-8What is not working for the Company
PRE-TAX PROFIT(Q)
At CNY -0.53 MM has Fallen at -116.69%
NET PROFIT(Q)
At CNY -0.38 MM has Fallen at -113.38%
DEBT-EQUITY RATIO
(HY)
Highest at -68.26 %
Here's what is working for Shanghai Serum Bio-Technology Co., Ltd.
Operating Cash Flow
Highest at CNY 80.2 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Raw Material Cost
Fallen by -8.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanghai Serum Bio-Technology Co., Ltd.
Pre-Tax Profit
At CNY -0.53 MM has Fallen at -116.69%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CNY MM)
Net Profit
At CNY -0.38 MM has Fallen at -113.38%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Debt-Equity Ratio
Highest at -68.26 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Non Operating Income
Highest at CNY 4.6 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income






